November 28, 2014 9:55 AM ET

Biotechnology

Company Overview of ProNAi Therapeutics, Inc.

Company Overview

ProNAi Therapeutics, Inc. develops and commercializes therapies that target DNA to treat patients with cancer and other complex genetic diseases. It develops nucleic acid-based DNAi technology, a gene-silencing drug that attacks cancer and prolongs survival by turning off cancer genes at their source with a small piece of DNA delivered in a fatty particle. The company’s PNT2258 is designed to treat cancers that overexpress BCL2. Its products pipeline also includes drug candidates to treat non-Hodgkin’s lymphoma, melanoma, prostate, breast, and colon cancers. ProNAi Therapeutics, Inc. was incorporated in 2003 and is based in Plymouth, Michigan.

46701 Commerce Center Drive

Michigan Life Science and Innovation Center

Plymouth, MI 48170

United States

Founded in 2003

Phone:

734-233-3967

Key Executives for ProNAi Therapeutics, Inc.

Chief Executive Officer and President
Age: 45
Chief Financial Officer
Chief Scientific Officer and Vice President of Product Development
Age: 48
Chief Business & Strategy Officer and Head of Commercial
Chief Medical Officer
Age: 58
Compensation as of Fiscal Year 2014.

ProNAi Therapeutics, Inc. Key Developments

ProNAi Therapeutics, Inc. Announces Executive Changes

ProNAi Therapeutics, Inc. announced the appointment Nick Glover, Ph.D. as president and chief executive officer. The company's previous CEO, Mina Sooch, will be leaving the organization to pursue new opportunities. Dr. Glover, an accomplished biotech executive, brings to ProNAi Therapeutics extensive experience in the field of oncology drug development. Dr. Glover most recently served as President and Chief Executive Officer of YM BioSciences Inc. Previously, Dr. Glover was President and Chief Executive Officer of Viventia Biotech Inc. He currently serves on the board of directors of MEI Pharma Inc.

ProNAi Therapeutics, Inc. Presents at 2014 Wells Fargo Healthcare Conference, Jun-17-2014 02:20 PM

ProNAi Therapeutics, Inc. Presents at 2014 Wells Fargo Healthcare Conference, Jun-17-2014 02:20 PM. Venue: InterContinental Hotel Boston, 510 Atlantic Avenu, Boston, MA 02210, United States. Speakers: Mina Patel Sooch, Chief Executive Officer, President and Director.

ProNAi Therapeutics Mulls IPO

ProNAi Therapeutics, Inc. has engaged a major New York investment bank to start raising $30 million and planning for an initial public offering by the end of 2014. Chief Executive Officer Mina Sooch says ProNAi is poised to take advantage of the results of its phase two Food and Drug Administration. Mina Sooch said she cannot name the New York investment bank, which has a focus on health care companies, because it requires confidentiality until it has successfully raised money.

Similar Private Companies By Industry

Company Name Region
Bioren, Inc. United States
SphynKx Therapeutics LLC United States
Biopolymer Innovations, LLC United States
Agilvax, Inc. United States
OrphageniX, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
April 17, 2014
--
Private Placement
January 10, 2014
--
Private Placement
December 20, 2013
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ProNAi Therapeutics, Inc., please visit www.pronai.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.